Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

BACKGROUND: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Stefano, Buecher, Bruno, André, Thierry, Jary, Marine, Bidard, François-Clément, Ghiringhelli, François, François, Éric, Taieb, Julien, Smith, Denis, de la Fouchardière, Christelle, Desramé, Jérôme, Samalin, Emmanuelle, Parzy, Aurélie, Baba-Hamed, Nabil, Bouché, Olivier, Tougeron, David, Dahan, Laëtitia, El Hajbi, Farid, Jacquin, Marion, Rebucci-Peixoto, Magali, Spehner, Laurie, Vendrely, Véronique, Vernerey, Dewi, Borg, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183720/
https://www.ncbi.nlm.nih.gov/pubmed/32334548
http://dx.doi.org/10.1186/s12885-020-06841-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183720/
https://www.ncbi.nlm.nih.gov/pubmed/32334548
http://dx.doi.org/10.1186/s12885-020-06841-1

Ejemplares similares